Ingavirin capsules 90mg №7×1

Name Ingavirin caps. On the cap of the capsule there is a white logo in the form of a ring and the letter And inside the ring. Composition One capsule contains: Active substance: pentanedioic acid imidazolylethanamide (vitaglutam) – 90.00 mg Excipients: lactose monohydrate, potato starch, colloidal silicon dioxide (aerosil), magnesium stearate. The composition of the capsule shell: titanium dioxide E 171, crimson dye Ponceau 4R E 124, azorubine dye E 122, quinoline yellow dye E 104, gelatin. The composition of the ink for the logo: shellac, propylene glycol E 1520, titanium dioxide E 171. Pharmacotherapeutic group Antiviral agents for systemic use. Antivirals of direct action. ATC code: J05AX. Pharmacological properties Pharmacodynamics Antiviral drug. In preclinical and clinical studies, the effectiveness of the drug Ingavirin® against influenza viruses type A (A (H1N1), including “pork” A (H1N1) pdm09, A (H3N2), A (H5N1)) and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in preclinical studies: coronavirus, metapneumovirus, enteroviruses, including Coxsackie virus and rhinovirus. The drug Ingavirin® promotes accelerated elimination of viruses, shortening the duration of the disease, and reducing the risk of complications. The mechanism of action is realized at the level of infected cells by stimulating innate immunity factors suppressed by viral proteins. In experimental studies, in particular, it has been shown that Ingavirin® increases the expression of the first type of interferon receptor IFNAR on the surface of epithelial and immunocompetent cells. An increase in the density of interferon receptors leads to an increase in the sensitivity of cells to the signals of endogenous interferon. The process is accompanied by activation (phosphorylation) of the STAT1 transmitter protein, which transmits a signal to the cell nucleus for the induction of antiviral genes. It has been shown that under conditions of infection, the drug stimulates the production of the antiviral effector protein MxA, which inhibits the intracellular transport of ribonucleoproteins of various viruses, slowing down the process of viral replication. The drug Ingavirin® causes an increase in the content of interferon in the blood to the physiological norm, stimulates and normalizes the reduced ?-interferon producing ability of blood leukocytes, stimulates ?-interferon producing ability of leukocytes. Causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells with high killer activity against virus-infected cells. The anti-inflammatory effect is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-?), interleukins (IL-1? and IL-6)), a decrease in the activity of myeloperoxidase. Experimental studies have shown that the combined use of Ingavirin® with antibiotics increases the effectiveness of therapy in a model of bacterial sepsis, including that caused by penicillin-resistant strains of staphylococcus aureus. Conducted experimental toxicological studies indicate a low level of toxicity and a high safety profile of the drug. According to the parameters of acute toxicity, the drug Ingavirin® belongs to the 4th class of toxicity – “Low-toxic substances” (when determining LD50 in experiments on acute toxicity, lethal doses of the drug could not be determined). The drug does not have mutagenic, immunotoxic, allergenic and carcinogenic properties, does not have a local irritating effect. The drug Ingavirin® does not affect the reproductive function, does not have an embryotoxic and teratogenic effect. Pharmacokinetics Absorption and distribution. In the recommended doses, the determination of the drug in the blood plasma by available methods is not possible. In an experiment using a radioactive label, it was found that the drug quickly enters the bloodstream from the gastrointestinal tract. Evenly distributed throughout the internal organs. Peak concentrations in blood, plasma and most organs are reached 30 minutes after drug administration. The AUC values (area under the concentration-time pharmacokinetic curve) of the kidneys, liver and lungs slightly exceed the blood AUC (43.77 μg h / g). The AUC values for the spleen, adrenal glands, lymph nodes and thymus are lower than the blood AUC. MRT (mean retention time of the drug) in the blood – 37.2 hours. With a course of taking the drug once a day, it accumulates in the internal organs and tissues. At the same time, the qualitative characteristics of the pharmacokinetic curves after each injection of the drug were identical: a rapid increase in the concentration of the drug after each injection 0.5-1 hour after administration and then a slow decrease by 24 hours. Metabolism. The drug is not metabolized in the body and is excreted unchanged. Withdrawal. The main elimination process occurs within 24 hours. During this period, 80% of the dose taken is excreted: 34.8% is excreted in the time interval from 0 to 5 hours and 45.2% in the time interval from 5 to 24 hours. Of these, 77% is excreted through the intestines and 23% through the kidneys. Indications for use Treatment and prevention of influenza A and B and other acute respiratory viral infections (adenoviral infection, parainfluenza, respiratory syncytial infection). Dosage and administration Inside. Regardless of food intake. For the treatment of influenza and acute respiratory viral infections, adults are prescribed 90 mg 1 time per day. The duration of treatment is 5-7 days (depending on the severity of the condition). The drug is started from the moment the first symptoms of the disease appear, preferably no later than 2 days from the onset of the disease. For the prevention of influenza and acute respiratory viral infections after contact with sick persons, adults are prescribed 90 mg 1 time per day for 7 days. Elderly patients: dose adjustment is not required. Patients with impaired liver and / or kidney function: dose adjustment is not required. Side effects Allergic reactions (rare). Contraindications Hypersensitivity to the active substance or any other component of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Pregnancy. breastfeeding period. Children’s age up to 18 years. Overdose Cases of drug overdose are not described. Precautions The drug does not have a sedative effect, does not affect the speed of the psychomotor reaction and can be used in people of various professions, incl. requiring increased attention and coordination of movements. The simultaneous use of other antiviral drugs is not recommended. Information related to the auxiliary components that make up the drug. The capsules contain dyes quinoline yellow (E 104), azorubine (E 122), crimson Ponceau 4R (E 124), which can cause allergic reactions. The drug contains lactose, so it should not be used in patients with rare congenital galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption. Use during pregnancy and lactation The use of the drug during pregnancy has not been studied. The use of the drug during lactation has not been studied, therefore, if necessary, the use of the drug during lactation should stop breastfeeding. Influence on the ability to drive vehicles, mechanisms It has not been studied, however, given the mechanism of action and the profile of adverse reactions, it can be assumed that the drug does not affect the ability to drive vehicles, mechanisms. Interaction with other medicinal products No cases of interaction of Ingavirin® with other medicinal products have been identified. Conditions and shelf life In a place protected from light and moisture at a temperature not exceeding 25 ° C. Keep out of the reach of children. 3 years. Do not use after the expiration date. Holiday conditions Without a prescription. Packing: 7 capsules in a blister pack made of PVC film and printed lacquered aluminum foil. 1 blister pack, together with instructions for medical use, is placed in a pack. Buy Ingavirin capsules 90mg No. 7×1 Price for Ingavirin capsules 90mg No. 7×1